6533b835fe1ef96bd129f552
RESEARCH PRODUCT
Carbapenem-Susceptible OXA-23-Producing Proteus mirabilis in the French Community
Patrick PlésiatAnaïs PotronDidier HocquetPauline TriponneyXavier BertrandBenoît Valotsubject
CarbapenemHospitalized patientsspreadclonalityMicrobial Sensitivity Testsbeta-LactamasesEpidemiology and SurveillanceMicrobiology03 medical and health sciencescarbapenemasemedicinepolycyclic compoundsHumansPharmacology (medical)Proteus mirabilis030304 developmental biologyCommunity onsetPharmacology0303 health sciencesbiologyOXA-23030306 microbiologybiochemical phenomena metabolism and nutritionbiology.organism_classificationProteus mirabilisAnti-Bacterial AgentsInfectious DiseasesReduced susceptibility[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyCarbapenemsbacteriaFranceProteus Infectionsmedicine.drugdescription
International audience; Nineteen Proteus mirabilis isolates producing the carbapenemase OXA-23 were recovered over a 2-year period in 19 French hospitalized patients, of whom 12 had community onset infections. The isolates exhibited a slightly reduced susceptibility to carbapenems. Whole-genome analysis revealed that all 19 isolates formed a cluster compared to 149 other P. mirabilis isolates. Because of its susceptibility to carbapenems, this clone may be misidentified as a penicillinase producer while it constitutes a reservoir of the OXA-23-encoding gene in the community.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-06-01 |